Recursion Pharmaceuticals (RXRX) Non Operating Income (2020 - 2026)

Recursion Pharmaceuticals has reported Non Operating Income for 7 years, with the latest figure at $6.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income rose 156.73% year-over-year to $6.4 million; the trailing twelve-month figure through Mar 2026 stood at $20.9 million (up 1774.22% YoY), and the FY2025 full-year result was $3.2 million, down 77.23% from the prior year.
• Non Operating Income for Q1 2026 stood at $6.4 million, up from $232000.0 in the prior quarter.
• The five-year high for Non Operating Income was $10.0 million in Q3 2025, with the low at -$11.3 million in Q1 2025.
• Historically, Non Operating Income has averaged $2.8 million across 5 years, with a median of $3.5 million in 2022.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 226800.0% — and 2025, when it slumped 369.27%.
• Recursion Pharmaceuticals' Non Operating Income stood at $3.5 million in 2022, then sank by 46.36% to $1.9 million in 2023, then surged by 160.1% to $4.9 million in 2024, then tumbled by 95.24% to $232000.0 in 2025, then surged by 2657.33% to $6.4 million in 2026.
• The last three Non Operating Income figures came in at $6.4 million (Q1 2026), $232000.0 (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.